Influence of demographic and disease parameters on virological response to once-vs twice-daily darunavir/ritonavir (DRV/r) at week 48 in ODIN 
Methods
Week 48 VR (HIV-1 RNA <50 copies/mL; ITT-TLOVR) was analysed by subgroups including gender, age, race, HIV clade, BL HIV-1 RNA and CD4 count.
Results
Week 48 VR was 72.1% for DRV/r qd vs 70.9% for bid (95% CI = -6.1 to 8.5%). Week 48 VR by gender, age, race, HIV clade, BL CD4 count and HIV-1 RNA is reported (Table 1) .
Conclusions
VR was comparable with DRV/r qd and bid regardless of subgroup analysed. As the trial was not powered for treatment comparisons in subgroups, and as numbers were small for some subgroups, these exploratory findings should be interpreted with caution. 
